McGowan BM, Bruun JM, Capehorn M, et al; STEP 10 Study Group. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): A randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. Published online July 29, 2024. doi:10.1016/S2213-8587(24)00182-7
Source link : https://www.medscape.com/s/viewarticle/semaglutide-2-4-mg-benefits-people-obesity-and-prediabetes-2024a1000epc?src=rss
Author :
Publish date : 2024-08-13 13:00:00
Copyright for syndicated content belongs to the linked Source.
